Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation

Research output: Contribution to journalReview article

136 Citations (Scopus)

Abstract

Tumors create an abnormal state of tolerance toward themselves and their antigens. One mechanism that might contribute to this tolerance is the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO). IDO-expressing antigen-presenting cells are found in tumor-draining lymph nodes, where they can create a tolerogenic microenvironment. IDO can also be expressed within the tumor itself, by tumor cells or host stromal cells, where it can inhibit the effector phase the immune response. Finally, emerging evidence suggests that IDO might also constitute a significant counter-regulatory mechanism, induced by clinically relevant pro-inflammatory signals, such as IFN-γ, IFN-α, CpG oligodeoxynucleotides, and 4-1BB ligation. Strategies to inhibit the IDO pathway may thus assist in breaking tolerance to tumors, and might enhance the efficacy of other immunotherapy strategies by removing unwanted counter-regulation.

Original languageEnglish (US)
Pages (from-to)220-225
Number of pages6
JournalCurrent Opinion in Immunology
Volume18
Issue number2
DOIs
StatePublished - Apr 1 2006

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Neoplasms
Oligodeoxyribonucleotides
Antigen-Presenting Cells
Stromal Cells
Immunotherapy
Ligation
Lymph Nodes
Antigens
Enzymes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. / Munn, David H.

In: Current Opinion in Immunology, Vol. 18, No. 2, 01.04.2006, p. 220-225.

Research output: Contribution to journalReview article

@article{3f45084b06094c70948ad68824c55c77,
title = "Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation",
abstract = "Tumors create an abnormal state of tolerance toward themselves and their antigens. One mechanism that might contribute to this tolerance is the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO). IDO-expressing antigen-presenting cells are found in tumor-draining lymph nodes, where they can create a tolerogenic microenvironment. IDO can also be expressed within the tumor itself, by tumor cells or host stromal cells, where it can inhibit the effector phase the immune response. Finally, emerging evidence suggests that IDO might also constitute a significant counter-regulatory mechanism, induced by clinically relevant pro-inflammatory signals, such as IFN-γ, IFN-α, CpG oligodeoxynucleotides, and 4-1BB ligation. Strategies to inhibit the IDO pathway may thus assist in breaking tolerance to tumors, and might enhance the efficacy of other immunotherapy strategies by removing unwanted counter-regulation.",
author = "Munn, {David H}",
year = "2006",
month = "4",
day = "1",
doi = "10.1016/j.coi.2006.01.002",
language = "English (US)",
volume = "18",
pages = "220--225",
journal = "Current Opinion in Immunology",
issn = "0952-7915",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation

AU - Munn, David H

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Tumors create an abnormal state of tolerance toward themselves and their antigens. One mechanism that might contribute to this tolerance is the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO). IDO-expressing antigen-presenting cells are found in tumor-draining lymph nodes, where they can create a tolerogenic microenvironment. IDO can also be expressed within the tumor itself, by tumor cells or host stromal cells, where it can inhibit the effector phase the immune response. Finally, emerging evidence suggests that IDO might also constitute a significant counter-regulatory mechanism, induced by clinically relevant pro-inflammatory signals, such as IFN-γ, IFN-α, CpG oligodeoxynucleotides, and 4-1BB ligation. Strategies to inhibit the IDO pathway may thus assist in breaking tolerance to tumors, and might enhance the efficacy of other immunotherapy strategies by removing unwanted counter-regulation.

AB - Tumors create an abnormal state of tolerance toward themselves and their antigens. One mechanism that might contribute to this tolerance is the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO). IDO-expressing antigen-presenting cells are found in tumor-draining lymph nodes, where they can create a tolerogenic microenvironment. IDO can also be expressed within the tumor itself, by tumor cells or host stromal cells, where it can inhibit the effector phase the immune response. Finally, emerging evidence suggests that IDO might also constitute a significant counter-regulatory mechanism, induced by clinically relevant pro-inflammatory signals, such as IFN-γ, IFN-α, CpG oligodeoxynucleotides, and 4-1BB ligation. Strategies to inhibit the IDO pathway may thus assist in breaking tolerance to tumors, and might enhance the efficacy of other immunotherapy strategies by removing unwanted counter-regulation.

UR - http://www.scopus.com/inward/record.url?scp=33644649659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644649659&partnerID=8YFLogxK

U2 - 10.1016/j.coi.2006.01.002

DO - 10.1016/j.coi.2006.01.002

M3 - Review article

C2 - 16460921

AN - SCOPUS:33644649659

VL - 18

SP - 220

EP - 225

JO - Current Opinion in Immunology

JF - Current Opinion in Immunology

SN - 0952-7915

IS - 2

ER -